Nominations close on Friday, September 4
Virtual Forum - October 13
Non-invasive prenatal testing market accounted for over US$ 1.5 Bn in 2019. It is anticipated to grow at a CAGR of approximately 16.2% from 2019 to 2030.
The rising prevalence of genetic disorders owing to increasing maternal age is promoting applications of Non-Invasive Prenatal Testing (NIPT) for early detection in fetal stages. For instance, the risk of fetus having Down syndrome is about 1 in 1,250 for women who conceive at the age of 25. The risk increases to about 1 in 100 for women who conceive at the age of 40. Moreover, there are several agreements signed for the promotion of NIPT. For instance, in February 2018, Harvard Pilgrim signed a value-based contract with Illumina, Inc. to enable wider patient access to the next generation of noninvasive testing for the detection of prenatal genetic abnormalities. However, the complexities associated with Non-Invasive Prenatal Testing (NIPT) require trained professionals, which pose serious concern for growth of the market.
Get sample copy of “Non-Invasive Prenatal Testing (NIPT) Market” at: https://www.marketindustryreports.com/pdf/269
Non-Invasive Prenatal Testing involves replacing invasive testing methods, which pose serious risks to developing fetuses. Non-Invasive Prenatal Testing (NIPT) is an emerging technology, which can be performed within 9 weeks of pregnancy and involves no risk of miscarriage. In addition, it offers clinical benefits over existing prenatal screening tests, such as maternal serum screening (MSS), by detecting the presence of trisomy 21 (Down syndrome, DS) with high sensitivity (99.9%) and specificity (98%). Moreover, there are several campaigns and programs conducted to spread awareness regarding Non-Invasive Prenatal Testing (NIPT) for the early detection of genetic abnormalities. This, in turn, contributes to growth of the Non-Invasive Prenatal Testing market.
Increasing developmental strategies by key players, such as agreements, collaborations, and new product launches, in different regions are promoting market growth. For instance, in April 2019, Thermo Fisher Scientific and NX Prenatal Inc. entered into a collaboration for the development of clinical mass spectrometry-based proteomics assays to monitor maternal & fetal health during pregnancy and provide noninvasive risk assessments of pregnancy outcomes. Similarly, some key players are focusing on providing access to comprehensive NIPT solutions across various regions. For instance, in June 2019, BGI Genomics and Eluthia launched BGI’s leading non-invasive prenatal test, NIFTY in Germany. The test screens for trisomies 21, 18, 13 with a sensitivity rate of over 99%. In addition, it also has additional screening options for 93 other trisomies, sex chromosomal aneuploidies, and deletion/duplication syndromes.
Browse key industry insights spread across 160 pages with market data tables & figures & charts from the report, Non-Invasive Prenatal Testing (NIPT) Market by Product (Consumables, Instruments, and Services), Method (Biochemical Screening Tests, Ultrasound Detection, Cell-Free DNA in Maternal Plasma Tests, and Fetal Cells in Maternal Blood Tests), Application (Trisomy and Microdeletion Syndrome), End User (Diagnostic Laboratories and Hospitals) - Global Analysis & Forecast 2019-2030 in detail along with the table of contents: https://www.marketindustryreports.com/non-invasive-prenatal-testing-NIPT-market/269
There are certain biologic factors, such as obesity among mothers expressed by a high body mass index and early gestational age, which leads to unreliable results of NIPT. Uninformative test results due to insufficient isolation of cell-free fetal DNA obtained pregnant women that are obese would eventually lead to delays in diagnosis and eliminate information related to risk assessment.
Asia Pacific is estimated to account for the highest CAGR in the Non-Invasive Prenatal Testing market over the forecast period. Improving healthcare facilities, increasing focus on fetal & maternal health and rising government initiatives are propelling market growth in this region. Moreover, extensive research for the development of better NIPT to screen a wide range of disorders is promoting market growth in this region. For instance, Chinese researchers have developed a fast, low-cost, and non-invasive maternal blood test for prenatal screening of Spinal Muscular Atrophy (SMA). The method provides a safer alternative to traditional invasive prenatal screenings for families with a history of SMA and other high-risk populations by identifying the affected fetuses within the first trimester.
Some of the prominent players in the non-invasive prenatal testing market include:
llumina, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, QIAGEN, BGI, Agilent Technologies, Inc., Natera, Inc., YOURGENE HEALTH, CENTOGENE N.V., and PerkinElmer Inc., among others.
Have any Query? Ask Here @ https://www.marketindustryreports.com/inquiry/269
Market Industry Reports is a global leader in market measurement and advisory services. It is a 100% subsidiary of ExlTech. The firm has always been at the forefront of innovations to address worldwide industry trends and opportunities. We offer our clients a unique depth of market intelligence in an actionable format to move their business forward. Our analysis incorporates consumer study in more than 100 countries, providing a tactical approach to drive sustained business growth. We continue to pioneer state-of-the-art approach in research & analysis that will help you to overcome complexities and stay ahead of the curve. By nurturing the perception of genius and optimized market intelligence, we unfold contingencies for our clients in the evolving world of technology, mega-trends, and industry convergence. We inspire our clients to empower and shape their businesses and to build world-class products.